These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36754130)

  • 1. Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes.
    Dalsgaard NB; Gasbjerg LS; Helsted MM; Hansen LS; Hansen NL; Skov-Jeppesen K; Hartmann B; Holst JJ; Vilsbøll T; Knop FK
    Bone; 2023 May; 170():116687. PubMed ID: 36754130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.
    Dalsgaard NB; Gasbjerg LS; Hansen LS; Hansen NL; Stensen S; Hartmann B; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2021 Mar; 184(3):383-394. PubMed ID: 33449919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis.
    Helsted MM; Gasbjerg LS; Lanng AR; Bergmann NC; Stensen S; Hartmann B; Christensen MB; Holst JJ; Vilsbøll T; Rosenkilde MM; Knop FK
    Bone; 2020 Nov; 140():115553. PubMed ID: 32730920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial.
    Hansen LS; Gasbjerg LS; Brønden A; Dalsgaard NB; Bahne E; Stensen S; Hellmann PH; Rehfeld JF; Hartmann B; Wewer Albrechtsen NJ; Holst JJ; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2024 Aug; 191(2):192-203. PubMed ID: 39049802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes.
    Bergmann NC; Lund A; Gasbjerg LS; Jørgensen NR; Jessen L; Hartmann B; Holst JJ; Christensen MB; Vilsbøll T; Knop FK
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2953-2960. PubMed ID: 30848791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of endogenous GIP in patients with type 2 diabetes.
    Stensen S; Gasbjerg LS; Krogh LL; Skov-Jeppesen K; Sparre-Ulrich AH; Jensen MH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Knop FK
    Eur J Endocrinol; 2021 May; 185(1):33-45. PubMed ID: 33886495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study.
    Skov-Jeppesen K; Veedfald S; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B
    Bone; 2021 Nov; 152():116065. PubMed ID: 34153529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men.
    Skov-Jeppesen K; Svane MS; Martinussen C; Gabe MBN; Gasbjerg LS; Veedfald S; Bojsen-Møller KN; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B
    Bone; 2019 Aug; 125():178-185. PubMed ID: 31100534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Gut-Bone Axis in Diabetes.
    Maagensen H; Helsted MM; Gasbjerg LS; Vilsbøll T; Knop FK
    Curr Osteoporos Rep; 2023 Feb; 21(1):21-31. PubMed ID: 36441432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between Postprandial Gut Hormones and Markers of Bone Remodeling.
    Jensen NW; Clemmensen KKB; Jensen MM; Pedersen H; Færch K; Diaz LJ; Quist JS; Størling J
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced postprandial bone resorption and greater rise in GLP-1 in overweight and obese individuals after an α-glucosidase inhibitor: a double-blinded randomized crossover trial.
    Kreitman A; Schneider SH; Hao L; Schlussel Y; Bello NT; Shapses SA
    Osteoporos Int; 2021 Jul; 32(7):1379-1386. PubMed ID: 33432459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
    Bergmann NC; Gasbjerg LS; Heimbürger SM; Krogh LSL; Dela F; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Lund A; Knop FK
    Diabetes Care; 2020 Mar; 43(3):588-596. PubMed ID: 31949084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia.
    Christensen MB; Lund A; Calanna S; Jørgensen NR; Holst JJ; Vilsbøll T; Knop FK
    J Clin Endocrinol Metab; 2018 Jan; 103(1):288-294. PubMed ID: 29099978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of gastrointestinal hormones in postprandial reduction of bone resorption.
    Henriksen DB; Alexandersen P; Bjarnason NH; Vilsbøll T; Hartmann B; Henriksen EE; Byrjalsen I; Krarup T; Holst JJ; Christiansen C
    J Bone Miner Res; 2003 Dec; 18(12):2180-9. PubMed ID: 14672353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GIP(3-30)NH
    Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
    Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
    Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.